Ian Judson

47.0k total citations · 9 hit papers
403 papers, 28.0k citations indexed

About

Ian Judson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ian Judson has authored 403 papers receiving a total of 28.0k indexed citations (citations by other indexed papers that have themselves been cited), including 252 papers in Pulmonary and Respiratory Medicine, 169 papers in Oncology and 79 papers in Molecular Biology. Recurrent topics in Ian Judson's work include Sarcoma Diagnosis and Treatment (200 papers), Vascular Tumors and Angiosarcomas (85 papers) and Gastrointestinal Tumor Research and Treatment (62 papers). Ian Judson is often cited by papers focused on Sarcoma Diagnosis and Treatment (200 papers), Vascular Tumors and Angiosarcomas (85 papers) and Gastrointestinal Tumor Research and Treatment (62 papers). Ian Judson collaborates with scholars based in United Kingdom, Netherlands and France. Ian Judson's co-authors include Jaap Verweij, M. van Glabbeke, Cyril Fisher, Jean‐Yves Blay, Paolo G. Casali, Ole S. Nielsen, Allan T. van Oosterom, Pancras C.W. Hogendoorn, Robin L. Jones and Joseph Thomas and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Ian Judson

399 papers receiving 27.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

2006 1.9k citations Jaap Verweij, Ian Judson et al. profile →
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

1989 1.5k citations Ian Judson et al. profile →
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

2004 1.3k citations Jaap Verweij, Jean‐Yves Blay et al. profile →
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

2001 975 citations Ian Judson, Jaap Verweij et al. profile →
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

2014 814 citations Ian Judson, Jaap Verweij et al. profile →
Soft-Tissue Sarcomas in Adults

2005 669 citations Cyril Fisher, Ian Judson et al. profile →
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

2006 654 citations Axel Le Cesne, Jean‐Yves Blay et al. European Journal of Cancer profile →
Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

2009 624 citations M. van Glabbeke, Axel Le Cesne et al. Cancer Research profile →
UK guidelines for the management of soft tissue sarcomas

2016 295 citations Beatrice Seddon, R. J. Grimer et al. profile →

Peers

Countries citing papers authored by Ian Judson

Since Specialization

Citations

This map shows the geographic impact of Ian Judson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Judson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Judson more than expected).

Fields of papers citing papers by Ian Judson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Judson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Judson. The network helps show where Ian Judson may publish in the future.

Co-authorship network of co-authors of Ian Judson

This figure shows the co-authorship network connecting the top 25 collaborators of Ian Judson. A scholar is included among the top collaborators of Ian Judson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Judson. Ian Judson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata 2023 ·British Journal of Cancer ·Penella J. Woll, Piers Gaunt, Charlotte Gaskell, Robin Young, Charlotte Benson, Ian Judson, Beatrice Seddon, Maria Marples, Nasim Ali, Sandra J. Strauss, (unknown), Ana Hughes, Baljit Kaur, David J. Hughes, Lucinda Billingham	5
2	Systemic therapy is effective in the management of leiomyomatosis 2022 ·European Journal of Gynaecological Oncology ·Alannah Smrke, (unknown), (unknown), Aisha Miah, Khin Thway, Cyril Fisher, Desmond P.J. Barton, (unknown), Ian Judson, Paul H. Huang, Robin L. Jones, Charlotte Benson, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
3	Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis 2022 ·Cancers ·Lukáš Krásný, (unknown), Emma Perkins, (unknown), (unknown), Andrew Jenks, Cyril Fisher, Ian Judson, Khin Thway, Robin L. Jones, Paul H. Huang	3
4	New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC – Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas 2022 ·European Journal of Cancer ·(unknown), Saskia Litière, Anouk Neven, (unknown), Ian Judson, Jean‐Yves Blay, Eva Wardelmann, Silvia Stacchiotti, Lorenzo D’Ambrosio, Sandrine Marréaud, Winette T.A. van der Graaf, Bernd Kasper, Marta Fiocco, Hans Gelderblom	7
5	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas 2021 ·European Journal of Cancer ·(unknown), Saskia Litière, Anouk Neven, (unknown), Ian Judson, Patrick Schöffski, Eva Wardelmann, Silvia Stacchiotti, Lorenzo D’Ambrosio, Sandrine Marréaud, Winette T.A. van der Graaf, Bernd Kasper, Marta Fiocco, Hans Gelderblom	7
6	Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma 2014 ·Clinical Cancer Research ·Ian Judson, Michelle Scurr, Kate Gardner, (unknown), Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, Michael Leahy	47
7	Targeting protein kinase C in sarcoma 2014 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Juan Martín-Liberal, Angus J.M. Cameron, Jeroen Claus, Ian Judson, Peter J. Parker, Mark Linch	8
8	Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma 2013 ·Sarcoma ·Juan Martín-Liberal, Salma Alam, Anastasia Constantinidou, Cyril Fisher, Komel Khabra, Christina Messiou, David Olmos, Scott C. Mitchell, Omar Al‐Muderis, Aisha Miah, Mark Linch, Robin L. Jones, Michelle Scurr, Ian Judson, Charlotte Benson	50
9	A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors 2011 ·Clinical Cancer Research ·Simon Pacey, Richard H. Wilson, Mike Walton, Martin Eatock, Anthea Hardcastle, (unknown), Hendrik‐Tobias Arkenau, (unknown), Udai Banerji, Belle Roels, (unknown), Wynne Aherne, Johann S. de Bono, Florence I. Raynaud, Paul Workman, Ian Judson	154
10	Histone Deacetylase Inhibition Increases Levels of Choline Kinase α and Phosphocholine Facilitating Noninvasive Imaging in Human Cancers 2011 ·Cancer Research ·Mounia Beloueche‐Babari, (unknown), Helen Troy, Robert te Poele, (unknown), L. Elizabeth Jackson, Geoffrey S. Payne, John R. Griffiths, Ian Judson, Paul Workman, Martin O. Leach, Yuen‐Li Chung	23
11	Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors 2009 ·Molecular Cancer Therapeutics ·Richard D. Baird, Jos Kitzen, Paul A. Clarke, André Planting, (unknown), Alison Reid, (unknown), Luis López Lázaro, Begoña de las Heras, Ian Judson, Stan B. Kaye, Ferry A.L.M. Eskens, Paul Workman, Johann S. de Bono, Jaap Verweij	33
12	Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents 2009 ·Cancer Research ·Yuval Shaked, Terence Tang, Jill Woloszynek, Laura G.M. Daenen, Shan Man, Ping Xu, Shi-Rong Cai, Jeffrey M. Arbeit, Emile E. Voest, David J. Chaplin, Jon Smythe, Adrian L. Harris, Paul Nathan, Ian Judson, Gordon Rustin, Francesco Bertolini, Daniel C. Link, Robert S. Kerbel	64
13	Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers 2007 ·Clinical Cancer Research ·Ruth Plummer, Gerhardt Attard, Simon Pacey, (unknown), Albiruni R. Abdul Razak, Rebecca M. Perrett, Mary Barrett, Ian Judson, Stan B. Kaye, Norma Lynn Fox, Wendy Halpern, A. Corey, Hilary Calvert, Johann S. de Bono	198
14	A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors 2007 ·Molecular Cancer Therapeutics ·Simon Pacey, Richard H. Wilson, Mike Walton, (unknown), (unknown), Hendrik‐Tobias Arkenau, Heidi Steinfeldt, Florence I. Raynaud, Paul Workman, Ian Judson	2
15	Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models 2005 ·Clinical Cancer Research ·Udai Banerji, Michael I. Walton, Florence I. Raynaud, Rachel Grimshaw, Lloyd R. Kèlland, (unknown), Ian Judson, Paul Workman	126
16	A Gene Expression Signature Associated with Metastatic Outcome in Human Leiomyosarcomas 2004 ·Cancer Research ·Yin-Fai Lee, (unknown), Alison Falconer, S M Edwards, Jeremy Clark, Penny Flohr, Toby Roe, Rubin Wang, Janet Shipley, R. J. Grimer, D. Chas Mangham, Joseph Thomas, Cyril Fisher, Ian Judson, Colin S. Cooper	59
17	Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: A STBSG-EORTC trial 2000 ·Annals of Oncology ·Axel Le Cesne, Ian Judson, John Radford, Jean‐Yves Blay, A. van Oosterom, Sjoerd Rodenhuis, Paul Lorigan, (unknown), José Jimeno, Jaco J. Verweij	9
18	Randomized Phase II Study of Docetaxel versus Doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. 2000 ·International Journal of Clinical Oncology ·Jaap Verweij, (unknown), W. Ruka, J. Buesa, Robert L. Coleman, Q.G.C.M. van Hoesel, C. Seynaeve, Eugenio Donato Di Paola, M. van Glabbeke, (unknown), Ian Judson	30
19	Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group study of 255 patients 1996 ·Cancer ·(unknown), Ugo Pastorino, (unknown), Ian Judson, Frits van Coevorden, (unknown), Ole S. Nielsen, Alain Boudinet, (unknown), Paul Schmitz	65
20	Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients 1996 ·Cancer ·A.N. van Geel, Ugo Pastorino, K. W. Jauch, Ian Judson, Frits van Coevorden, J. Buesa, Ole S. Nielsen, Alain Boudinet, (unknown), Paul Schmitz	200

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact